National Institutes of Health: all 11,571 studies

Page 38 of 116. Open to participants first (946), then studies with results posted, then the rest; newest registration first within each.

• Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment InterruptionActive, not recruitingNCT04340596Phase 1
• Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and VolunteersCompletedNCT04339790
• Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s DiseaseWithdrawnNCT04339751Phase 2
• SARS-COV2 Pandemic Serosurvey and Blood SamplingCompletedNCT04334954
• Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerActive, not recruitingNCT04334941Phase 2
• Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIVWithdrawnNCT04334915Phase 2
• Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCLActive, not recruitingNCT04324112Phase 2
• Evaluation and Follow-up of People With Tick-borne DiseasesWithdrawnNCT04318925
• Ask Suicide-Screening Questions (ASQ) for Youth With Autism Spectrum and Neurodevelopmental DisordersCompletedNCT04317118
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENActive, not recruitingNCT04317105Phase 1/2
• MK-7075 (Miransertib) in Proteus SyndromeActive, not recruitingNCT04316546Phase 2
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsActive, not recruitingNCT04310020Phase 2
• Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04310007Phase 2
• Dietary Behavior Intervention in African Americans at Risk for Cardiovascular DiseaseActive, not recruitingNCT04305431Not applicable
• Testing the Biological Effects of DS-8201a on Patients With Advanced CancerActive, not recruitingNCT04294628Phase 1
• M7824 Related Adverse Effects in Adults With CancerActive, not recruitingNCT04267861
• Assisted Suicide in SwitzerlandActive, not recruitingNCT04261088
• Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesActive, not recruitingNCT04235777Phase 1
• Collecting Interval Timed Incisional Epidermal and Dermal Tissue Samples During Surgical Procedures to Profile Temporal Response of Tissue After Noxious StimuliCompletedNCT04224870
• A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE TrialActive, not recruitingNCT04216290Phase 2
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial CancerActive, not recruitingNCT04214067Phase 3
• Radium-223 in Biochemically Recurrent Prostate CancerActive, not recruitingNCT04206319Phase 2
• A Single Patient Will be Treated With Individual Patient TCR-Transduced PBLNo longer availableNCT04194190
• Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04190550Phase 1
• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic CancerSuspendedNCT04172532Phase 1/2
• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerActive, not recruitingNCT04164082Phase 2
• National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerCompletedNCT04145141
• A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenActive, not recruitingNCT04145115Phase 2
• Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabNo longer availableNCT04135092
• Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT CarcinomaWithdrawnNCT04116359Phase 1/2
• Malaria Prevalence Around Maferinyah, GuineaCompletedNCT04105855
• Non-Viral TCR Gene TherapyWithdrawnNCT04102436Phase 2
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerActive, not recruitingNCT04092283Phase 3
• A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingNCT04092270Phase 1
• Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the BonesActive, not recruitingNCT04090398Phase 2
• Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyActive, not recruitingNCT04071236Phase 1/2
• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL StudyActive, not recruitingNCT04071223Phase 2
• Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesActive, not recruitingNCT04068194Phase 1/2
• Vaccine Response With NT-I7WithdrawnNCT04054752Phase 1
• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerActive, not recruitingNCT04052555Phase 1
• Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral TherapyWithdrawnNCT04046107Phase 1/2
• A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal CancerWithdrawnNCT04044950Phase 2
• Pediatric cGVHD Symptom ScaleActive, not recruitingNCT04044365
• Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult ParticipantsWithdrawnNCT04041674Phase 1
• Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) OralWithdrawnNCT04025567Phase 2
• Glutamine Supplementation in People With Immune DysregulationWithdrawnNCT04019769Early Phase 1
• Characterization of Fatigue in Military Personnel With Traumatic Brain InjuriesWithdrawnNCT03998358
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasActive, not recruitingNCT03984448Phase 2/3
• Mapping Institutional Identities and the Production of EthicsCompletedNCT03983863
• Optimizing PTCy Dose and TimingActive, not recruitingNCT03983850Phase 1/2
• Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous DiseaseCompletedNCT03983837Phase 2
• Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03983824Phase 1
• Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate CancerActive, not recruitingNCT03976843Phase 2
• Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)Active, not recruitingNCT03964090Phase 2
• Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle NephropathyCompletedNCT03958643
• Patient-Centered Assessment of Symptoms and OutcomesCompletedNCT03952624
• Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR SpectroscopySuspendedNCT03952598Phase 2
• Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaActive, not recruitingNCT03937830Phase 2
• New Approaches for Empowering Studies of Asthma in Populations of African DescentCompletedNCT03937804
• Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 DiabetesActive, not recruitingNCT03929601Phase 2
• Structural Heart and Valve Network PROSPECTIVE RegistryWithdrawnNCT03928639
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
• Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell LymphomaActive, not recruitingNCT03922724Phase 2
• Skin Immunity Sample Collection Involving Blisters and BiopsiesWithdrawnNCT03921515Early Phase 1
• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruitingNCT03919071Phase 2
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaActive, not recruitingNCT03914625Phase 3
• Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant CyclophosphamideActive, not recruitingNCT03910452Early Phase 1
• An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)CompletedNCT03908632
• Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)WithdrawnNCT03895658Phase 1
• Safety and Efficacy of Pegvisomant in Children With Growth Hormone ExcessCompletedNCT03882034Phase 3
• The National Institutes of Health Measure of Healing Experience of All Life StressorsCompletedNCT03871270
• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaActive, not recruitingNCT03871257Phase 3
• Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM)TerminatedNCT03867435
• Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate CancerCompletedNCT03860987Phase 2
• Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple MyelomaWithdrawnNCT03856112Phase 1/2
• Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaActive, not recruitingNCT03854474Phase 1/2
• Evaluation of Intranasal Naltrexone and NaloxoneCompletedNCT03851731Phase 1
• Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular RouteCompletedNCT03845231Phase 2
• Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome MeasuresCompletedNCT03845218
• Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With CancerActive, not recruitingNCT03827343
• Retrospective Chart Review of Candida FungemiaCompletedNCT03827330
• Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerActive, not recruitingNCT03816358Phase 1
• TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased BlastsActive, not recruitingNCT03816319Phase 1
• Testing Immunotherapy Versus Observation in Patients With HPV Throat CancerActive, not recruitingNCT03811015Phase 3
• A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerWithdrawnNCT03803761Phase 1/2
• CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT03798678Phase 1
• Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 MutationsWithdrawnNCT03794297Phase 2
• Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerActive, not recruitingNCT03793179Phase 3
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingNCT03793166Phase 3
• Exploring the Relationship Between Brain Asymmetry and AttentionCompletedNCT03789201Not applicable
• Characterizing Fatigue Experienced by Registered NursesTerminatedNCT03789188
• Prevalence and Incidence of Lassa Virus Infection in Southern MaliCompletedNCT03783143
• Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerActive, not recruitingNCT03775265Phase 3
• Natural History Study of Children and Adults With Fibrolamellar Hepatocellular CarcinomaWithdrawnNCT03748927
• Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT03745352Phase 2
• PREVAIL VIII: A CoHOrt Clinical, Viral, and ImmuNOlogic Monitoring Study of People Living With Retroviral Infection in Liberia (HONOR)CompletedNCT03733093
• Large-Scale Online Studies of Early Motor Skill LearningCompletedNCT03733080
• Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) HaploinsufficiencyWithdrawnNCT03733067Phase 1/2
• Optimization of Collection Methods for Studies of the Human MicrobiotaWithdrawnNCT03731702

← National Institutes of Health overview and focus areas